Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 May 1;35(6):861-868.
doi: 10.1097/QAD.0000000000002839.

Prospective evaluation of blood Epstein-Barr virus DNA load and antibody profile in HIV-related non-Hodgkin lymphomas

Julien Lupo  1 , Raphaële Germi  1 , Rémi Lancar  2 , Michèle Algarte-Genin  2 , Houria Hendel-Chavez  3 , Yassine Taoufik  4 , Nicolas Mounier  5 , Marialuisa Partisani  6 , Fabrice Bonnet  7 , Marie-Caroline Meyohas  8 , Bruno Marchou  9 , Anastasiia Filippova  1 , Sophie Prevot  10 , Dominique Costagliola  2 , Patrice Morand  1 , Caroline Besson  11   12
Affiliations

Prospective evaluation of blood Epstein-Barr virus DNA load and antibody profile in HIV-related non-Hodgkin lymphomas

Julien Lupo et al. AIDS. .

Abstract

Objectives: The value of Epstein-Barr virus (EBV) biomarkers on the prognosis of HIV-related non-Hodgkin's lymphoma (NHL) has been poorly explored in the combined antiretroviral therapy (cART) era.

Design: We evaluated EBV DNA load and EBV antibodies in HIV-NHL patients enrolled in the French ANRS-CO16 Lymphovir Cohort between 2008 and 2015.

Methods: Whole blood and plasma EBV DNA load and serological profiles were analyzed in 76 HIV-infected patients at diagnosis of NHL and 6 months after the initiation of chemotherapy.

Results: Prechemotherapy whole blood (WB) and plasma EBV DNA loads were positive for 80 and 45% of HIV-NHL patients, respectively. Pretreatment WB EBV DNA positivity was associated with a positive plasma HIV-1 RNA load (relative risk (RR), 4.42 [1.33; 14.72]) and plasma EBV DNA positivity with EBV in situ detection (RR 10.62 [2.38; 47.49]). Following chemotherapy, the proportions of patients with positive WB or plasma EBV DNA declined from 81 to 23% (P < 0.0001) and from 43 to 8% (P < 0.0001), respectively. Estimated 2-year progression-free survival did not differ according to prechemotherapy WB positivity (82% versus 67%, P = 0.15) or plasma EBV DNA positivity (76% versus 81%, P = 0.52).

Conclusions: The plasma EBV DNA load correlates with in situ EBV detection. The WB EBV DNA load correlates with HIV load. WB and plasma EBV DNA loads at NHL diagnosis do not constitute prognostic markers for HIV-NHL patients in the modern cART era.

PubMed Disclaimer

References

    1. Simard EP, Engels EA. Cancer as a cause of death among people with AIDS in the United States . Clin Infect Dis 2010; 51:957–962.
    1. Lanoy E, Spano J-P, Bonnet F, et al. The spectrum of malignancies in HIV-infected patients in 2006 in France: the ONCOVIH study . Int J Cancer 2011; 129:467–475.
    1. Vandenhende M-A, Roussillon C, Henard S, et al. Cancer-related causes of death among HIV-infected patients in France in 2010: evolution since 2000 . PLoS One 2015; 10:e0129550doi: 10.1371/journal.pone.0129550. - DOI
    1. Arvey A, Ojesina AI, Pedamallu CS, et al. The tumor virus landscape of AIDS-related lymphomas . Blood 2015; 125:e14–e22.
    1. Carbone A, Volpi CC, Gualeni AV, Gloghini A. Epstein – Barr virus associated lymphomas in people with HIV . Curr Opin HIV AIDS 2017; 12:39–46.

Publication types